02-09-2016: Poietis successfully bio-printed living human tissue with using a proprietary laser-assisted 3D bioprinting technology
The world's first successful application of laser bioprinting to produce functional biological tissue
On February 9, 2016, the French biotechnology company Poietis announced a breakthrough in bioprinting technology, proving that its proprietary laser-assisted 3D bioprinting method allows for the creation of living human tissue with unprecedented precision and cell viability, marking the world's first successful application of laser bioprinting to produce functional biological tissue.
Founded in 2014 by Fabien Guillemot as a spin-off of INSERM (the French National Institute of Health and Medical Research) and the University of Bordeaux, Poietis developed a unique laser bioprinting technology (LBP – Laser-Assisted Bioprinting), enabling the precise layer-by-layer deposition of cells with micrometric accuracy; unlike traditional extrusion-based bioprinting methods that rely on bioink, laser bioprinting utilizes a laser beam to precisely position individual cells onto a substrate.
This technology provides better control over biological structures and enhances cell survival, which is crucial for creating functional tissues, and Poietis refers to its approach as 4D bioprinting, as it takes into account structural and functional changes in tissues over time, a key factor in bioengineering.
The company focuses on three main areas: tissue engineering for the cosmetic industry, developing bioprinted skin models for cosmetic testing to eliminate animal testing; regenerative medicine, advancing technologies for creating complex tissues such as bioprinted skin grafts and cartilage; and pharmaceuticals, bioprinting tissues for drug testing in conditions more closely resembling the human body.
From the outset, Poietis deliberately limited its scope to bioprinting skin and corneas rather than competing in the race to bioprint fully transplantable organs, with Fabien Guillemot emphasizing that their goal is tissue repair rather than enhancement or modification.
Today, the company continues to develop its technologies and conduct research on the medical applications of bioprinting, with its NGB bioprinters used by research laboratories and medical institutions across Europe and beyond.
Source: www.3ders.org